Company Encyclopedia
View More
name
Arcellx
ACLX.US
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS.
1.944 T
ACLX.USMarket value -Rank by Market Cap -/-

Financial Score

24/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking198/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-47.18%E
    • Profit Margin-607.01%E
    • Gross Margin-608.99%E
  • Growth ScoreE
    • Revenue YoY-76.96%E
    • Net Profit YoY-439.06%E
    • Total Assets YoY-14.25%E
    • Net Assets YoY-8.75%D
  • Cash ScoreE
    • Cash Flow Margin-16.47%D
    • OCF YoY-76.96%E
  • Operating ScoreE
    • Turnover0.05E
  • Debt ScoreB
    • Gearing Ratio32.80%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    3 'Strong Buy' Stocks to Buy Today,12/23/2025, According to Top Analysts

    Top Wall Street analysts have given Strong Buy ratings to three stocks: CG Oncology (CGON), WhiteFiber (WYFI), and Arcellx (ACLX). CGON has a price target of $90 with an 81.79% upside, WYFI has a price target of $34 with a 92.74% upside, and ACLX has a price target of $100 with a 30.75% upside. All analysts covering these stocks have rated them as Buys in the last three months.

    Tip Ranks·
    US
    ACLX
    +0.75%
    US
    CGON
    +0.22%
    US
    WYFI
    -1.53%
    Tip Ranks·
    US
    ACLX
    +0.75%
    US
    CGON
    +0.22%
    US
    WYFI
    -1.53%

    Arcellx a new overweight at Wells Fargo on promise of multiple myeloma CAR-T asset

    Wells Fargo initiated coverage of Arcellx (ACLX) with an overweight rating, citing its promising CAR-T therapy for multiple myeloma, anito-cel. The bank set a price target of $100, predicting significant market capture and rapid uptake post-2026 launch. Analyst Yanan Zhu forecasts peak sales of $1.6B in the fourth line and $3.8B in the second line. Arcellx is developing anito-cel with Kite Pharma, owned by Gilead Sciences (GILD).

    MSN·
    US
    ACLX
    +0.75%
    MSN·
    US
    ACLX
    +0.75%

    Arcellx Inc (ACLX) Gets a Buy from Piper Sandler

    Piper Sandler analyst Biren Amin maintained a Buy rating on Arcellx Inc with a $115 price target. Amin, a 4-star analyst, has a 6.8% average return and a 46.69% success rate. Canaccord Genuity also issued a Buy rating, while TR downgraded Arcellx to a Sell on December 9.

    Tip Ranks·
    US
    ACLX
    +0.75%
    Tip Ranks·
    US
    ACLX
    +0.75%

    Arcellx (NASDAQ:ACLX) Given Buy Rating at Canaccord Genuity Group

    Canaccord Genuity Group reiterated a "buy" rating for Arcellx (NASDAQ:ACLX) with a $130 price target, indicating a potential 70.27% upside. Eight analysts rate the stock as Buy, with a consensus rating of "Moderate Buy" and an average target price of $115.50. Arcellx's stock traded at $76.35, with a market cap of $4.41 billion. Insiders sold shares worth $3,030,736 recently, and institutional investors own 96.03% of the stock.

    Market Beat·
    US
    ACLX
    +0.75%
    Market Beat·
    US
    ACLX
    +0.75%

    Arcellx shares jump on strong multiple myeloma trial results

    Arcellx Inc. (NASDAQ:ACLX) rallied 13.6% in premarket trading Monday after releasing encouraging data from its pivotal Phase 2 iMMagine-1 trial evaluating anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma. In the latest update, the company reported a 96% overall response rate and a 74% complete response/stringent complete response rate at a median […]

    MSN·
    US
    ACLX
    +0.75%
    MSN·
    US
    ACLX
    +0.75%
    © 2025 Longbridge｜Disclaimer